Article summary
The Association of the British Pharmaceutical Industry (ABPI) has announced that it suspended Novo Nordisk as a member of ABPI for two years due to serious breaches of the ABPI Code of Practice. An investigation by the Prescription Medicines Code of Practice Authority (PMCPA) found Novo Nordisk to have breached the ABPI Code of Practice, including Clause 2 which deals with actions 'likely to bring discredit on, or reduce confidence in, the pharmaceutical industry'. Novo Nordisk will not be able to access the wider benefits of ABPI membership and the will be subject to further audits further audits in late 2023 and 2024.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial